What does 'selective' actually mean when comparing SARMs to anabolic steroids?

Selectivity refers to a compound's ability to activate target receptors in specific tissues (e.g., muscle) while minimising activation in non-target tissues (e.g., prostate). Classic AAS bind androgen receptors indiscriminately. SARMs exploit receptor-coactivator interactions to achieve partial tissue preference. SR9009 takes a different route — it targets REV-ERB proteins entirely outside the androgen receptor pathway, making 'selectivity' a different concept altogether.

Are SARMs genuinely safer than steroids in terms of side effects?

SARMs reduce certain androgenic side effects compared to AAS — lower aromatization, reduced DHT-driven effects — but they are not side-effect-free. HPG axis suppression occurs with most SARMs, requiring PCT. Hepatotoxicity risk is lower than with oral 17-alpha-alkylated AAS but not zero. Independent HPLC testing (as used by Vital Research) is critical because unlabelled compounds or incorrect concentrations amplify all risk categories unpredictably.

Where does tissue selectivity break down with SARMs?

Selectivity breaks down primarily at the HPG axis. Even tissue-selective SARMs suppress LH and FSH by signalling through hypothalamic androgen receptors, reducing endogenous testosterone. This suppression is compound- and dose-dependent — stronger SARMs like S-23 suppress more aggressively than ostarine at equivalent doses. SR9009 does not suppress via this pathway because REV-ERB agonism does not interface with gonadotropin regulation.

Why is 8mg per tablet the highest concentration in this format, and how does it affect dosing?

At 8 mg per tablet, Vital Research's Stenabolic tablets align with the lower boundary of the research dose range (typically 20–30 mg/day split across doses), allowing users to start at one tablet and titrate upward in 8 mg increments without tablet splitting. This precision matters because SR9009 has a short half-life of approximately 4–5 hours, making consistent, measured multi-dose scheduling more practical with a tablet that matches the incremental dose unit.

Does Stenabolic SR9009 require post-cycle therapy (PCT) like SARMs or steroids do?

No PCT is typically indicated for SR9009 based on its mechanism. Because SR9009 does not bind androgen receptors or signal through the HPG axis, it does not suppress LH, FSH, or endogenous testosterone production. This differentiates it clearly from both AAS and most SARMs. However, users stacking SR9009 with androgenic compounds should manage PCT based on the androgenic agent in the stack, not SR9009 itself. (2) angle_used

Lab Tested

Vital Research

Stenabolic 8mg/tab 30 Tablets by Vital Research

Name: Stenabolic
Brand: Vital Research
SKU: SARM-STEN-VIT-001
Price: 48.00 EUR
Availability: InStock

Stenabolic (SR9009) is a synthetic REV-ERB agonist — not a classic androgen receptor modulator — formulated at 8 mg per tablet across a 30-tablet blister, targeting metabolic and circadian pathways rather than androgenic tissue. Unlike anabolic-androgenic steroids, SR9009 exerts its effects without binding androgen receptors, which fundamentally changes the selectivity equation and the associated side-effect profile. Quality is embedded at the lot level: every blister undergoes HPLC-verified potency testing and LAL endotoxin screening before release, with GMP-aligned raw-material controls upstream.

€48.00Free shipping on orders over €300

In stock

Ships within 48 h Lab-tested batch

Targets REV-ERB α/β receptors — an androgenic side-effect pathway avoided by design
8 mg per tablet enables clean, incremental dosing across SR9009's short 4–5 hour half-life
No aromatization and no DHT conversion — estrogen management not required from this compound
Supports mitochondrial biogenesis and fatty acid oxidation via circadian gene regulation
HPLC-confirmed potency on every lot — concentration stated on label is concentration delivered
Blister format preserves tablet integrity across the full 30-unit pack
Compatible with both standalone research protocols and non-androgenic stacking strategies

Phase	dosage	Note
Orientation (Week 1–2)	8 mg/day (1 tablet)	Assess individual response to REV-ERB agonism; no androgenic baseline adjustment required
Standard Research Phase (Week 3–6)	16–24 mg/day (2–3 tablets split across day)	Split doses every 4–5 hours to compensate for short half-life; aligns with circadian dosing rationale
Selectivity Assessment (ongoing)	Maintain chosen dose; no HPG axis monitoring required for SR9009 alone	If stacked with androgenic compounds, monitor testosterone suppression from the androgenic agent, not SR9009
Discontinuation	No taper required for SR9009	PCT not indicated based on REV-ERB mechanism; resume normal routine immediately

Key takeaways

Understand that SR9009 bypasses androgen receptors entirely, unlike SARMs or steroids.
Choose 8mg tablets for precise multi-dose scheduling across SR9009's short half-life.
Verify REV-ERB agonism carries no HPG axis suppression, eliminating standard PCT requirements.
Confirm Lab Tested status: each lot is HPLC-verified and LAL endotoxin screened.
Compare selectivity profiles before stacking SR9009 with androgenic compounds.

SR9009 as a Non-Androgenic Research Compound: Understanding Tissue Selectivity

Stenabolic (SR9009) is a REV-ERB α/β agonist that modulates mitochondrial biogenesis, glucose metabolism, and circadian clock genes — a mechanism of action categorically distinct from the androgen-receptor pathway exploited by both classic anabolic-androgenic steroids (AAS) and most SARMs. This distinction matters because androgenic selectivity is the primary axis on which SARMs are differentiated from AAS: SARMs such as LGD-4033 or S-23 bind the androgen receptor with tissue-preferential affinity, whereas SR9009 bypasses the androgen receptor entirely. Vital Research supplies SR9009 at 8 mg per tablet — the highest per-tablet concentration in its single-ingredient oral REV-ERB range — delivering precise dosing without splitting.

Selectivity Compared: SARMs vs. Steroids vs. SR9009

Classic AAS activate androgen receptors systemically, producing anabolic effects in muscle alongside androgenic effects in the prostate, skin, and hair follicles — a coupling that defines their side-effect burden. SARMs partially decouple this by exploiting receptor conformation differences across tissues; preclinical data suggest tissue-selective partial agonism, though full androgenic suppression of the hypothalamic-pituitary-gonadal (HPG) axis remains a documented concern across the SARM class. SR9009 sidesteps androgenic suppression risk because REV-ERB agonism does not signal through the HPG axis — REV-ERB proteins regulate BMAL1/CLOCK gene expression, not testosterone biosynthesis. Compared to testosterone enanthate, SR9009 produces no aromatization and no direct DHT conversion, removing estrogen-related and androgenic side effects from the risk profile entirely.

Mechanism and Metabolic Targets

SR9009 activates REV-ERB receptors in skeletal muscle, liver, and adipose tissue, upregulating mitochondrial content and fatty acid oxidation while downregulating lipogenic gene expression. Research in rodent models (published in Nature Medicine, 2013, Burris et al.) demonstrated that SR9009 increased exercise capacity and reduced fat mass without caloric restriction — findings that drove research interest in the compound. Vital Research's HPLC verification protocol confirms that each 8 mg tablet delivers active SR9009 within specification, and LAL endotoxin testing confirms microbiological acceptability at the lot level.

Lab Testing and Documentation

Every 30-tablet blister produced by Vital Research is assigned a unique lot code tied to its compound-specific certificate of analysis. GMP-aligned manufacturing governs API sourcing, content uniformity, and blister sealing — ensuring that the selectivity advantages of the compound are not undermined by dosing inconsistency.

Usage

Establish your dosing schedule before starting: SR9009's ~4–5 hour half-life means single daily dosing is suboptimal — divide your daily total across 3 evenly spaced administrations.
Take each tablet orally with water; food is not required but consistent timing relative to meals improves routine adherence.
Begin at 8 mg/day (1 tablet) for the first 7–14 days to characterise individual metabolic response before increasing.
Increase to 16–24 mg/day in subsequent weeks by adding one tablet per dose period — the 8 mg per tablet format allows clean titration without splitting.
If stacking with a SARM or AAS, track androgenic suppression markers (LH, FSH, total testosterone) for the androgenic compound — SR9009 itself does not require HPG axis monitoring.
At cycle end, discontinue SR9009 directly; plan any PCT solely around androgenic co-compounds if present in the protocol.

Warnings

Contraindications: SR9009 is not approved for human therapeutic use by any regulatory body. Do not use if pregnant, breastfeeding, or under 18. Individuals with hepatic impairment should avoid use pending further pharmacokinetic data on REV-ERB agonists in compromised liver function.

Side Effects: Reported effects in research contexts include sleep pattern changes (consistent with circadian mechanism), gastrointestinal discomfort at higher doses, and transient fatigue during dose adjustment. Unlike AAS or most SARMs, androgenic side effects (acne, hair loss, virilisation) are not mechanism-consistent with SR9009.

Monitoring: Baseline and post-cycle liver enzyme panels (ALT, AST) are advisable. If combining with androgenic compounds, add LH, FSH, and total testosterone to the monitoring panel — but attribute any suppression to the androgenic agent, not SR9009.

PCT: Post-cycle therapy is not required based on SR9009's REV-ERB mechanism of action. No HPG axis suppression is expected from SR9009 alone. PCT should be planned only when SR9009 is used alongside androgenic or HPG-suppressive compounds.

Frequently asked questions

What does 'selective' actually mean when comparing SARMs to anabolic steroids?: Selectivity refers to a compound's ability to activate target receptors in specific tissues (e.g., muscle) while minimising activation in non-target tissues (e.g., prostate). Classic AAS bind androgen receptors indiscriminately. SARMs exploit receptor-coactivator interactions to achieve partial tissue preference. SR9009 takes a different route — it targets REV-ERB proteins entirely outside the androgen receptor pathway, making 'selectivity' a different concept altogether.
Are SARMs genuinely safer than steroids in terms of side effects?: SARMs reduce certain androgenic side effects compared to AAS — lower aromatization, reduced DHT-driven effects — but they are not side-effect-free. HPG axis suppression occurs with most SARMs, requiring PCT. Hepatotoxicity risk is lower than with oral 17-alpha-alkylated AAS but not zero. Independent HPLC testing (as used by Vital Research) is critical because unlabelled compounds or incorrect concentrations amplify all risk categories unpredictably.
Where does tissue selectivity break down with SARMs?: Selectivity breaks down primarily at the HPG axis. Even tissue-selective SARMs suppress LH and FSH by signalling through hypothalamic androgen receptors, reducing endogenous testosterone. This suppression is compound- and dose-dependent — stronger SARMs like S-23 suppress more aggressively than ostarine at equivalent doses. SR9009 does not suppress via this pathway because REV-ERB agonism does not interface with gonadotropin regulation.
Why is 8mg per tablet the highest concentration in this format, and how does it affect dosing?: At 8 mg per tablet, Vital Research's Stenabolic tablets align with the lower boundary of the research dose range (typically 20–30 mg/day split across doses), allowing users to start at one tablet and titrate upward in 8 mg increments without tablet splitting. This precision matters because SR9009 has a short half-life of approximately 4–5 hours, making consistent, measured multi-dose scheduling more practical with a tablet that matches the incremental dose unit.
Does Stenabolic SR9009 require post-cycle therapy (PCT) like SARMs or steroids do?: No PCT is typically indicated for SR9009 based on its mechanism. Because SR9009 does not bind androgen receptors or signal through the HPG axis, it does not suppress LH, FSH, or endogenous testosterone production. This differentiates it clearly from both AAS and most SARMs. However, users stacking SR9009 with androgenic compounds should manage PCT based on the androgenic agent in the stack, not SR9009 itself. (2) angle_used

Manufacturer

Vital Research's sterility and aseptic production controls are applied at the individual compound level rather than uniformly across the entire product range. For the Stenabolic line, aseptic handling begins at the API intake stage: raw SR9009 is accepted only after identity verification and chromatographic purity confirmation specific to the REV-ERB agonist molecular structure, before any tableting commences. Tablet compression and blister sealing are conducted under controlled environmental conditions — particulate limits, microbial action levels, and equipment cleaning validation are each documented per batch rather than audited periodically at the facility level. The result is a 30-tablet blister where HPLC-verified SR9009 content and LAL endotoxin data are traceable to the specific lot, not to a generalised facility quality statement.

Product details

Brand	Vital Research
Active ingredient	stenabolic
Also known as	stenabolic, Stenabolic, Vital Research stenabolic
Strength	8 mg
Form	Tabletten
Pack size	30 pieces
Item number	SARM-STEN-VIT-001

Reviews

No reviews yet. Be the first to review this product.

Write a review

Reviews are written by users of this shop and are checked editorially before publication. Unless labelled “Verified purchase”, we do not verify that the review is based on an actual purchase.

Similar products

Pharma Grade

Stenabolic (SR-9009) 10mg/tab 60 Tablets by Master Pharma

Stenabolic SR-9009 is a REV-ERB α/β agonist supplied here as a 10 mg tablet, notable among research compounds for operating through a non-hormonal pathway that leaves the hypothalamic-pituitary-testicular axis largely intact. Because SR-9009 does not bind androgen receptors, measurable HPTA suppression is typically absent or minimal, making post-cycle recovery substantially lighter than protocols required after anabolic agents. Quality assurance for every Master Pharma tablet batch is enforced through a dual-gate release system: HPLC active-content verification against a traceable reference standard, followed by LAL endotoxin testing before any unit reaches dispatch.

€70.00

Stack it with

Pairs well with these products.

High Concentration

Quant-Equipoise 300mg/ml 10ml Vial by Beligas Pharmaceuticals

Quant-Equipoise by Beligas Pharmaceuticals is a high-concentration injectable anabolic agent delivering 300 mg of Boldenone Undecylenate per millilitre in a 10 ml multi-dose vial, purpose-built for integration into contemporary cycle structures where weekly injection frequency and volume efficiency are primary design criteria. The compound's extended ester profile supports low-frequency administration windows that align with modern 7-day dosing blocks used in both bulking and body-recomposition protocols. Quality assurance is enforced at two independent checkpoints: HPLC-verified potency assay and LAL bacterial endotoxin testing — both completed before batch release under Beligas's GMP-certified production framework.

€47.00

Bolden-250 250mg/ml 10x1ml Ampoules by BM Pharmaceuticals

Long-Acting Formula

Bolden-250 250mg/ml 10x1ml Ampullen by BM Pharmaceuticals

Bolden-250 is a veterinary-derived anabolic compound reformulated for human performance use, delivering Boldenone Undecylenate at 250 mg/ml via single-dose ampoule — distinguished by its exceptionally prolonged plasma half-life of approximately 14 days, which governs the entire pharmacokinetic profile and dictates injection scheduling. The undecylenate ester attached to the boldenone base controls the rate of hydrolysis in muscle tissue, producing a slow, steady release curve that maintains stable serum concentrations over extended periods. Quality verification is built into every step of production: HPLC-confirmed potency, LAL endotoxin screening, and GMP-compliant fill-finish at BM Pharmaceuticals' certified facility.

€48.00

Brand Quality

EquiTrex 350mg/ml 10ml Vial by Concentrex Labs

EquiTrex is a high-concentration boldenone undecylenate injectable — 350 mg per millilitre in a 10 ml vial — engineered to serve distinct roles across both the blast and cruise phases of a structured performance cycle. Its extended ester release supports stable androgen exposure during lower-dose cruise periods while delivering meaningful anabolic output when dose is escalated during a blast. Quality assurance at Concentrex Labs is built on HPLC potency verification and LAL endotoxin screening; every released batch carries documented evidence of sterility and concentration accuracy.

€52.00

Pro Choice

EQ 300 300mg/ml 10ml Vial by Dragon-Pharma

Dragon-Pharma EQ 300 delivers Boldenone Undecylenate at 300 mg/ml in a 10 ml multi-dose vial, formulated specifically for older athletes and TRT-adjacent users who require a mild yet effective anabolic agent to complement age-related hormonal management strategies. Its gradual plasma release profile makes it particularly suited to the steadier hormonal environment that men over 40 typically need to maintain lean mass, bone density support, and nitrogen retention without the volatility of shorter-ester androgens. Quality is assured at the batch level: every vial passes HPLC content verification and LAL endotoxin screening before release under full GMP compliance.

€44.00